Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Note: See sections 5 and 6.

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------|----------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| 5039 | UBIDECARENONE | A, E | When used as an excipient, the route of administration must be topical and the concentration in the medicine must not be more than 0.05%. |
| | | | Not to be included in medicines intended for use in the eye. |
| | | | When for internal use, the maximum recommended daily dose must not provide more than 300 milligrams of ubidecarenone. |
| | | | When for internal use in combination with Ubiquinol-10, the maximum recommended daily dose must not provide more than 300 milligrams of ubiquinol-10 and ubidecarenone combined. |
| | | | When for internal use, the following warning statement is required on the medicine label: |
| | | | - (WARF) 'Do not take while on warfarin therapy without medical advice'. |
| 5040 | UBIQUINOL-10 | A, E | When used as an excipient, the route of administration must be topical and the concentration in the medicine must be no more than 0.05%. |
| | | | Not to be included in medicines intended for use in |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|------------------|----------|--|
| Item | Ingredient name | Purpose | Specific requirements |
| | | | the eye. |
| | | | When for internal use, the maximum recommended daily dose must provide no more than 300 milligrams of ubiquinol-10. |
| | | | When used in combination with ubidecarenone, the maximum recommended daily dose must provide no more than 300 mg of ubiquinol-10 and ubidecarenone combined. |
| | | | The medicine requires the following warning statement on the medicine label: |
| | | | - (WARF) 'Do not take while on warfarin therapy without medical advice.' |
| 5041 | ULEX EUROPAEUS | A, H | |
| 5042 | ULMUS AMERICANA | A, H | |
| 5043 | ULMUS CAMPESTRIS | A, H | |
| 5044 | ULMUS GLABRA | A, H | |
| 5045 | ULMUS PARVIFOLIA | A, H | |
| 5046 | ULMUS PROCERA | A, H | |
| 5047 | ULMUS PUMILA | A, H | |
| 5048 | ULMUS RUBRA | A, H | |
| 5049 | ULTRALIDE | Е | Permitted for use only in combination with other permitted ingredients as a fragrance. |
| | | | If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%. |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------|----------|---|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| 5050 | ULTRAMARINE BLUE | E | Permitted for use only as a colour for topical use. |
| 5051 | ULVA LACTUCA | A, H | Iodine is a mandatory component of Ulva lactuca. |
| | | | Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. |
| | | | The concentration in the medicine must be no more than 0.1%. |
| 5052 | UMBELLULARIA CALIFORNICA | A, H | |
| 5053 | UNCARIA GAMBIR | A, H | |
| 5054 | UNCARIA RHYNCOPHYLLA | A, H | |
| 5055 | UNCARIA SINENSIS | A, H | |
| 5056 | UNCARIA TOMENTOSA | A, H | |
| 5057 | UNDARIA PINNATIFIDA | A, H | Whole dried Undaria pinnatifida must not contain the holdfast. |
| | | | Only for use in oral medicines. |
| 5058 | UNDECANAL | Е | Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| | | | If used in a fragrance the total fragrance concentration in a medicine must be no more 1%. |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible in Column 1 | Column 2 | Column 3 | Column 4 |
|-------------------------|-------------------------------|----------|---|
| Item | Ingredient name | Purpose | Specific requirements |
| 5059 | UNDECANOIC ACID | Е | Permitted for use only in combination with other permitted ingredients as a flavour. |
| | | | If used as a flavour the total flavour concentration in a medicine must be no more than 5%. |
| 5060 | UNDECENOIC ACID | Е | |
| 5061 | UNDECYL ALCOHOL | Е | Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| | | | If used in a fragrance the total fragrance concentration in a medicine must be no more 1%. |
| 5062 | UNDECYLCRYLENE DIMETICONE | Е | Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. |
| | | | The concentration in the medicine must be no more than 10%. |
| 5063 | UNDECYLENAMIDE DEA | E | |
| 5064 | UNDECYLENOYL PEG-5 PARABEN | Е | Only for use in topical medicines for dermal application. |
| 5065 | URANIUM NITRATE | Н | Only for use as an active |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|---|----------|---|
| Item | Ingredient name | Purpose | Specific requirements |
| | | | homoeopathic ingredient. |
| 5066 | UREA | A, E, H | Only for use in topical medicines for dermal application. The concentration in the |
| | | | medicine must be no more than 10% (w/w). |
| 5067 | URTICA DIOICA | A, E, H | |
| 5068 | URTICA URENS | A, H | |
| 5069 | USNEA BARBATA | A, H | |
| 5070 | UVA URSI LEAF DRY | A, H | |
| 5071 | UVA URSI LEAF POWDER | A, E, H | |
| 5072 | VA/BUTYL MALEATE/ISOBORNYL ACRYLATE COPOLYMER | Е | Vinyl acetate is a mandatory component of VA/butyl maleate/isobornyl acrylate copolymer. |
| | | | The concentration of vinyl acetate in the medicine must be no more than 0.01% or 100 ppm. |
| | | | Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. |
| | | | The concentration in the medicine must be no more than 5%. |
| 5073 | VACCARIA SEGATALIS | A, H | |
| 5074 | VACCINIUM BRACTEATUM | A, H | |
| 5075 | VACCINIUM CORYMBOSUM | Е | Permitted for use only in combination with other permitted ingredients as a |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible ingredients and requirements | | | | |
|--|------------------------|----------|---|--|
| Column 1 | Column 2 | Column 3 | Column 4 | |
| Item | Ingredient name | Purpose | Specific requirements | |
| | | | flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. | |
| 5076 | VACCINIUM MACROCARPON | A, E, H | | |
| 5077 | VACCINIUM MYRTILLOIDES | A, H | | |
| 5078 | VACCINIUM MYRTILLUS | A, E, H | | |
| 5079 | VACCINIUM OXYCOCCUS | A, H | | |
| 5080 | VACCINIUM VITIS-IDAEA | А, Н | Arbutin is a mandatory component of Vaccinium vitisidaea. | |
| | | | The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg/L or 0.0025 % unless used on the hair. | |
| | | | When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %. | |
| 5081 | VALENCENE | Е | Permitted for use only in combination with other permitted ingredients as a flavour. | |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. | |
| 5082 | VALERALDEHYDE | Е | Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total | |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|-----------------------|----------|---|
| Item | Ingredient name | Purpose | Specific requirements |
| | | | flavour concentration in a medicine must be no more than 5%. |
| 5083 | VALERIAN DRY | A, H | |
| 5084 | VALERIAN OIL | Е | Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| 5085 | VALERIAN POWDER | A, H | |
| 5086 | VALERIANA EDULIS | A, H | |
| 5087 | VALERIANA OFFICINALIS | A, H | |
| 5088 | VALERIANA SORBIFOLIA | A, H | |
| 5089 | VALERIC ACID | Е | Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total |
| | | | flavour concentration in a medicine must be no more than 5%. |
| 5090 | VALINE | A, E | |
| 5091 | VANADIUM | Н | |
| 5092 | VANILLA | Е | Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|--------------------|----------|---|
| Item | Ingredient name | Purpose | Specific requirements |
| 1011 | ingi cutent nume | Turpose | medicine must be no more than 5%. |
| | | | If used in a fragrance the total fragrance concentration in a medicine must be no more 1%. |
| 5093 | VANILLA DRY | A, E, H | |
| 5094 | VANILLA EXTRACT | Е | Permitted for use only in combination with other permitted ingredients as a flavour. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| 5095 | VANILLA OLEORESIN | Е | Permitted for use only in combination with other permitted ingredients as a flavour. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| 5096 | VANILLA PLANIFOLIA | A, E, H | |
| 5097 | VANILLA POWDER | A, E, H | |
| 5098 | VANILLA TAHITENSIS | A, H | |
| 5099 | VANILLIC ACID | Е | Permitted for use only in combination with other permitted ingredients as a flavour. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|----------------------------------|----------|---|
| Item | Ingredient name | Purpose | Specific requirements |
| 5100 | VANILLIN | Е | |
| 5101 | VANILLIN ISOBUTYRATE | Е | Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| | | | If used in a fragrance the total fragrance concentration in a medicine must be no more 1%. |
| 5102 | VANILLYL ALCOHOL | Е | Permitted for use only in combination with other permitted ingredients as a flavour. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| 5103 | VAT RED 1 | E | Permitted for use only as a colour for topical use. |
| 5104 | VAT RED 1 ALUMINIUM LAKE | Е | Permitted for use only as a colour for topical use. |
| 5105 | VAT RED 5 | Е | Permitted for use only as a colour for topical use. |
| 5106 | VEGETABLE OIL | E | |
| 5107 | VEGETABLE OIL PHYTOSTEROL ESTERS | A | Only for use in oral medicines. The medicine requires the following warning statement on the medicine label: |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------|----------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| | | | recommended for use by pregnant and lactating women (or words to that effect).' |
| 5108 | VEIN | Н | Only for use as an active homoeopathic ingredient. |
| 5109 | VERATRALDEHYDE | Е | Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| | | | If used in a fragrance the total fragrance concentration in a medicine must be no more 1%. |
| 5110 | VERATROL | Е | Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. |
| | | | The total fragrance proprietary excipient formulation in a medicine must be no more than 1%. |
| 5111 | VERATRUM ALBUM | A, H | Solanidine is a mandatory component of Veratrum album. |
| | | | The concentration of equivalent dry Veratrum album in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%. |
| 5112 | VERBASCUM DENSIFLORUM | A, H | |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|--------------------------|----------|--|
| Item | Ingredient name | Purpose | Specific requirements |
| 5113 | VERBASCUM THAPSUS | A, H | |
| 5114 | VERBENA OFFICINALIS | A, H | |
| 5115 | VERBENA OIL | Е | Permitted for use only in combination with other permitted ingredients as a flavour. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| 5116 | VERONICA CHAMAEDRYS | A, H | |
| 5117 | VERONICA OFFICINALIS | A, H | |
| 5118 | VERONICASTRUM VIRGINICUM | A, E, H | |
| 5119 | VERTONAL | Е | Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. |
| | | | When included in a medicine for use on the lips the concentration of vertonal must be no more than 0.2%. |
| | | | The total fragrance proprietary excipient formulation in a medicine must be no more than 1%. |
| 5120 | VETIVER OIL | Е | Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| | | | If used in a fragrance the total fragrance concentration in a |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------------|----------|---|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| | | | medicine must be no more 1% |
| 5121 | VETIVERYL ACETATE | Е | Permitted for use only in combination with other permitted ingredients as a fragrance. |
| | | | If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%. |
| 5122 | VIBURNUM OPULUS | A, E, H | |
| 5123 | VIBURNUM PRUNIFOLIUM | A, E, H | |
| 5124 | VICIA FABA | A, H | Levodopa (of Vicia faba) is a mandatory component of Vicia faba. |
| | | | The concentration of Levodop (of Vicia faba) from all ingredients in the medicine must be no more than 1mg/kg or 1mg/L or 0.1%. |
| 5125 | VIGNA ANGULARIS VAR. ANGULARIS | A, H | |
| 5126 | VIGNA RADIATA | A, H | |
| 5127 | VIGNA UMBELLATA | A, H | |
| 5128 | VINCA MAJOR | A, H | Vincamine is a mandatory component of Vinca major. |
| | | | The concentration of vincamine in the medicine must be no more than 10mg/kg or 10 mg/L or 0.001%. |
| 5129 | VINCA MINOR | A, H | Vincamine and vincristine are mandatory components of Vinca minor. |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Permissible in | agredients and requirements | | |
|----------------|-----------------------------|----------|---|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| | | | The concentration of vincamine in the medicine must be no more than 10mg/k, or 10 mg/L or 0.001%. |
| | | | The concentration of Vincristine in the medicine must be no more than 10mg/k or 10mg/L or 0.001% |
| 5130 | VINCETOXICUM OFFICINALE | А, Н | |
| 5131 | VINEGAR | Е | Permitted for use only in combination with other permitted ingredients as a flavour. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more tha 5%. |
| 5132 | VIOLA ODORATA | A, E, H | |
| 5133 | VIOLA TRICOLOR | A, H | |
| 5134 | VIOLA YEDOENSIS | A, H | |
| 5135 | VIOLET LEAF ABSOLUTE | Е | Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more tha 5%. |
| | | | If used in a fragrance the total fragrance concentration in a medicine must be no more 1% |
| 5136 | VIOLET LEAVES | Е | Permitted for use only in combination with other permitted ingredients as a flavour. |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible in | gredients and requirements | | |
|----------------|--|----------|---|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| 5137 | VIPER | Н | Only for use as an active homoeopathic ingredient. |
| 5138 | VISCUM ALBUM | A, E, H | |
| 5139 | VISCUM COLORATUM | A, H | |
| 5140 | VISCUM FLAVESCENS | A, H | |
| 5141 | VITELLARIA PARADOXA | A, E, H | |
| 5142 | VITEX AGNUS-CASTUS | A, E, H | |
| 5143 | VITEX NEGUNDO | A, H | |
| 5144 | VITEX ROTUNDIFOLIA | A, H | |
| 5145 | VITEX TRIFOLIA | A, H | |
| 5146 | VITIS VINIFERA | A, E, H | |
| 5147 | VITREOSCILLA CONCENTRATE | E | Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 0.1%. |
| 5148 | VP/ACRYLATES/LAURYL METHACRYLATE COPOLYMER | E | Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must not be more than 2.00%. |
| 5149 | WAHLENBERGIA GRACILIS | A, H | |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------|----------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| 5150 | WALNUT | Е | |
| 5151 | WALNUT OIL | Е | |
| 5152 | WATER MELON | Е | |
| 5153 | WHEAT | Е | Gluten is a mandatory component of Wheat when the route of administration is other than topical and mucosal. |
| 5154 | WHEAT BRAN | E | Gluten is a mandatory component of Wheat bran when the route of administration is other than topical and mucosal. |
| 5155 | WHEAT DEXTRIN | A, E | Gluten is a mandatory component of wheat dextrin. Only for use when the dosage form is capsule, tablet or pill. |
| 5156 | WHEAT GERM | E | Gluten is a mandatory component of Wheat germ when the route of administration is other than topical and mucosal. |
| 5157 | WHEAT GERM GLYCERIDES | E | Gluten is a mandatory component of wheat germ glycerides when the route of administration is other than topical and mucosal. |
| 5158 | WHEAT LEAF | E | |
| 5159 | WHEAT SPROUT | Е | Gluten is a mandatory component of Wheat sprout when the route of administration is other than topical and mucosal. |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|--------------------------------|-----------|--|
| Item | Ingredient name | Purpose | Specific requirements |
| TCIII | ingredient name | 1 ur pose | Specific requirements |
| 5160 | WHEAT STARCH | E | When the route of administration is other than topical or mucosal, gluten is a mandatory component of whea starch. |
| 5161 | WHEATGERM OIL | A, E, H | |
| 5162 | WHEY POWDER | Е | Lactose is a mandatory component of Whey powder when the route of administration is oral. |
| 5163 | WHEY PROTEIN | Е | Lactose is a mandatory component of Whey protein when the route of administration is oral. |
| 5164 | WHEY PROTEIN CONCENTRATE | Е | Permitted for use only in combination with other permitted ingredients as a flavour. |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. |
| 5165 | WHITE BEESWAX | Е | |
| 5166 | WHITE HOREHOUND HERB DRY | A, H | |
| 5167 | WHITE HOREHOUND HERB POWDER | A, H | |
| 5168 | WHITE SOFT PARAFFIN | A, E | When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| | Permissible ingredients and requirements | | | | |
|----------|--|----------|---|--|--|
| Column 1 | Column 2 | Column 3 | Column 4 | | |
| Item | Ingredient name | Purpose | Specific requirements | | |
| | | | substance monograph of the British Pharmacopoeia, as in force or existing from time to time. | | |
| 5169 | WHOLE DRY MILK | Е | If the product is for oral ingestion and contains lactose, then the medicine requires the following warning statement on the medicine label: - (LACT) 'Contains lactose' (or | | |
| | | | words to that effect). | | |
| 5170 | WIKSTROEMIA VIRIDIFLORA | A, H | | | |
| 5171 | WILD CARROT HERB DRY | A, E, H | | | |
| 5172 | WILD CARROT HERB POWDER | A, H | | | |
| 5173 | WILD CHERRY BARK DRY | A, H | | | |
| 5174 | WILD CHERRY BARK POWDER | A, H | | | |
| 5175 | WILD LETTUCE LEAF DRY | A, H | | | |
| 5176 | WILD LETTUCE LEAF POWDER | A, H | | | |
| 5177 | WINTERGREEN OIL | A, E, H | Methyl salicylate is a mandatory component of wintergreen oil. | | |
| | | | Not to be included in medicines for use in the eye or on damaged skin. | | |
| | | | When used internally, the concentration of methyl salicylate in the medicine must not be more than 0.001%. | | |
| | | | When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is other than spray, the medicine requires child resistant packaging. | | |

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|-----------------|----------|--|
| Item | Ingredient name | Purpose | Specific requirements |
| | | | When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is spray, the medicine does not require child resistant packaging if: |
| | | | the delivery device is engaged into the container in such a way that prevents it from being readily removed; |
| | | | direct suction through the delivery device results in delivery of no more than one dosage unit; and |
| | | | - actuation of the spray device is ergonomically difficult for young children to accomplish. |
| | | | In addition, when the ingredient is included in a medicine that is listed in the Register: |
| | | | - on or after 1 July 2018, the medicine must comply with all requirements under (a) & (b); |
| | | | - before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a) & (b); or |
| | | | - before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with the requirements under (a) & (b). |
| | | | a) The following warning statement is required on the medicine label: |
| | | | - (METSAL) 'Contains methyl salicylate' (or words to that effect). |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------|----------|---|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| | | | b) When for use in topical medicines for dermal application, the concentration of methyl salicylate in the medicine must not be more than 25% and the following warning statements are required on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect); - (CHILD4) 'Do not use [this product/insert name of product in children 6 years of age or less'; - (SENS) 'Application to skin may increase sensitivity to sunlight'. (or words to that effect); - (IRRIT) 'If irritation develops, discontinue use.'; and - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect). |
| 5178 | WITHANIA SOMNIFERA | A, E, H | |
| 5179 | WOLFIPORIA COCOS | A, E, H | When the ingredient is included in a medicine that is listed in the Register before 1 July 2018 and supplied before 1 January 2020, the medicine label may refer to the ingredient name as 'Poria cocos' instead of 'Wolfiporia cocos'. |
| 5180 | WOOL ALCOHOLS | Е | Only for use in topical medicines for dermal application. |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible in | ngredients and requirements | | |
|----------------|------------------------------|----------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| 5181 | WOOL FAT | A, E | When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time. |
| 5182 | XANTHAN GUM | Е | |
| 5183 | XANTHIUM SIBIRICUM | A, H | |
| 5184 | XANTHIUM STRUMARIUM | A, H | |
| 5185 | XANTHOMONA CAMPESTRIS | A, H | |
| 5186 | XEROPHYLLUM ASPHODELOIDES | A, H | |
| 5187 | XYLENE | Е | The residual solvent limit for xylene is 21.7 mg per maximum recommended daily dose. The concentration in the medicine must be no more than 0.217%. |
| 5188 | XYLITOL | E | When the quantity of sugar alcohols per maximum recommended daily dose is more than 2g, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label: - (SUGOLS) 'Products containing [insert name of |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|-----------------------|----------|---|
| Item | Ingredient name | Purpose | Specific requirements |
| | | | sugar alcohol(s) may have a laxative effect or cause diarrhoea [or words to that effect]'. |
| 5189 | XYLOSE | Е | |
| 5190 | YAM | Е | |
| 5191 | YARROW HERB DRY | A, H | |
| 5192 | YARROW HERB POWDER | A, H | |
| 5193 | YEAST AUTOLYSATE | Е | |
| 5194 | YEAST DRIED | A, E, H | |
| 5195 | YELLOW 2G | Е | Permitted for use only as a colour for topical use. |
| 5196 | YELLOW BEESWAX | Е | |
| 5197 | YELLOW MERCURIC OXIDE | Н | Only for use as an active homoeopathic ingredient. |
| 5198 | YELLOW SOFT PARAFFIN | A, E | Only for use in topical medicines for dermal application. |
| | | | When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time. |
| 5199 | YLANG YLANG OIL | A, E, H | |
| 5200 | YUCCA BACCATA | A, H | |
| 5201 | YUCCA ELATA | A, H | |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible ingredients and requirements | | | |
|--|--|--|--|
| Column 2 | Column 3 | Column 4 | |
| Ingredient name | Purpose | Specific requirements | |
| YUCCA FILAMENTOSA | A, H | | |
| YUCCA GLORIOSA | A, H | | |
| YUCCA WHIPPLEI | A, H | | |
| ZANTHOXYLUM AMERICANUM | A, H | | |
| ZANTHOXYLUM BUNGEANUM | A, E, H | | |
| ZANTHOXYLUM CLAVA- HERCULIS | A, H | | |
| ZANTHOXYLUM NITIDUM | A, H | | |
| ZANTHOXYLUM PIPERITUM | A, H | | |
| ZANTHOXYLUM SIMULANS | A, H | | |
| ZEA MAYS | A, E, H | | |
| ZEAXANTHIN | A, E | | |
| ZEIN | Е | | |
| ZINC | Н | Only for use as an active homoeopathic ingredient. | |
| | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. | |
| | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that | |
| | Column 2 Ingredient name YUCCA FILAMENTOSA YUCCA GLORIOSA YUCCA WHIPPLEI ZANTHOXYLUM AMERICANUM ZANTHOXYLUM BUNGEANUM ZANTHOXYLUM CLAVA-HERCULIS ZANTHOXYLUM NITIDUM ZANTHOXYLUM PIPERITUM ZANTHOXYLUM SIMULANS ZEA MAYS ZEAXANTHIN ZEIN | Column 2 Ingredient name Purpose YUCCA FILAMENTOSA A, H YUCCA GLORIOSA A, H YUCCA WHIPPLEI A, H ZANTHOXYLUM AMERICANUM A, E, H ZANTHOXYLUM CLAVA- HERCULIS ZANTHOXYLUM NITIDUM A, H ZANTHOXYLUM PIPERITUM A, H ZANTHOXYLUM SIMULANS A, H ZEA MAYS A, E, H ZEAXANTHIN A, E | |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------|----------|---|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| 5215 | ZINC AMINO ACID CHELATE | A, E, H | When used internally, zinc is a mandatory component of zinc amino acid chelate. |
| | | | The concentration of zinc in zinc amino acid chelate must be no more than 30%. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be |
| | | | dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5216 | ZINC ASCORBATE | A, E, H | When used internally, zinc is a mandatory component of zinc ascorbate. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|-------------------------------|-------------|---|
| Item | Ingredient name | Purpose | Specific requirements |
| 200 | | 1 11 1 1000 | which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5217 | ZINC ASCORBATE MONOHYDRATE | A, E, H | When used internally, zinc is a mandatory component of zinc ascorbate monohydrate. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25 mg but no more than 50 mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zine which may be dangerous if taken in large amounts or for a long period (or words to that effect)'. |
| 5218 | ZINC CHLORIDE | A, E, H | The concentration of zinc chloride in the medicine must be no more than 5%. |
| | | | When used internally, zinc is a mandatory component of zinc chloride. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Permissible in | Permissible ingredients and requirements | | | | |
|----------------|--|----------|--|--|--|
| Column 1 | Column 2 | Column 3 | Column 4 | | |
| Item | Ingredient name | Purpose | Specific requirements | | |
| | | | dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' | | |
| 5219 | ZINC CITRATE | A, E, H | When used internally, zinc is a mandatory component of zinc citrate. | | |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. | | |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: | | |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' | | |
| 5220 | ZINC CITRATE DIHYDRATE | A, E, H | When used internally, zinc is a mandatory component of zinc citrate dihydrate. | | |
| | | | When for internal use, the | | |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------|----------|---|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| | | | maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5221 | ZINC CITRATE TRIHYDRATE | A, E, H | When used internally, zinc is a mandatory component of zinc citrate trihydrate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------|----------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| 5222 | ZINC DIASPARTATE | A | When used internally, zinc is a mandatory component of zinc diaspartate. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zin which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5223 | ZINC GLUCONATE | A, E, H | When used internally, zinc is a mandatory component of zinc gluconate. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible in Column 1 | Column 2 | Column 3 | Column 4 |
|-------------------------|-------------------------------|----------|--|
| Item | Ingredient name | Purpose | Specific requirements |
| | | <u> </u> | OR 'WARNING: Contains zind which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5224 | ZINC GLYCINATE | A | When used internally, zinc is a mandatory component of Zinc glycinate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5225 | ZINC GLYCINATE MONOHYDRATE | A | When used internally, zinc is a mandatory component of Zinc glycinate monohydrate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|------------------------|-----------|---|
| Item | Ingredient name | Purpose | Specific requirements |
| | ingi curent nume | T an pose | medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zing which may be dangerous if taken in large amounts or for a long period (or words to that effect)'. |
| 5226 | ZINC LACTATE | E | Only for use in topical and dental medicines and not to be included in medicines intended for use in the eye. |
| | | | The concentration of zinc lactate in a medicine intended for topical use should be no more than 2%. |
| | | | The concentration of Zinc lactate in a medicine for 'dental' use in toothpaste medicines must be no more than 2.5%. |
| | | | Zinc lactate is not to be included in dental / toothpaste medicines intended for use by children less than 12 years old. |
| | | | Medicines containing Zinc lactate for dental use require the following warning statement on the medicine label: |
| | | | - (CHILD3) 'Use in children under 12 years is not recommended'. |
| 5227 | ZINC LACTATE DIHYDRATE | Е | Only for use in topical and dental medicines and not to be |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| | gredients and requirements | Calan 2 | Column A |
|----------|----------------------------|----------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements included in medicines intended |
| | | | for use in the eye. |
| | | | The concentration of Zinc lactate dihydrate in a medicine intended for topical use should be no more than 2%. |
| | | | The concentration of Zinc lactate dihydrate in a medicine for 'dental' use in toothpaste medicines must be no more than 2.5%. |
| | | | Zinc lactate dihydrate is not to be included in dental / toothpaste medicines intended for use by children less than 12 years old. |
| | | | Medicines containing Zinc lactate for dental use require the following warning statement on the medicine label: |
| | | | - (CHILD3) 'Use in children under 12 years is not recommended'. |
| 5228 | ZINC LYSINATE | A | When used internally, zinc is a mandatory component of Zinc lysinate. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| | ngredients and requirements | | |
|----------|-----------------------------|----------|---|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5229 | ZINC METHIONINE SULFATE | A | For topical use, the concentration of zinc methionine sulfate must be no more than 5%. |
| | | | When used internally, zinc is a mandatory component of zinc methionine sulfate. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5230 | ZINC MYRISTATE | Е | Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible in | ngredients and requirements | | |
|----------------|-----------------------------|----------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| | | | medicine must be no more than 0.1%. |
| 5231 | ZINC OXIDE | A, E, H | When used internally, zinc is a mandatory component of zinc oxide. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR |
| | | | -'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| | | | When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label: |
| | | | - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and |
| | | | - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect). |
| | | | When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| | ngredients and requirements | C. L | Calarra A |
|----------|-------------------------------|----------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | requires the following statements on the medicine label if supplied after 1 July 2019: - (AVOID) 'Avoid prolonged exposure in the sun' (or words |
| | | | to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect). |
| 5232 | ZINC PARA- PHENOLSULFONATE | Е | The concentration of zinc paraphenolsulfonate in the medicine must not exceed 5%. |
| | | | When used internally, zinc is a mandatory component of zinc para-phenolsulfate. |
| | | | The percentage of zinc from zinc para-phenolsulfonate should be calculated based on the molecular weight of zinc para-phenolsulfonate. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period' (or words to that |
| 5233 | ZINC STEARATE | E | effect). When used internally, zinc is a |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Column 1 | Column 2 | Column 3 | Column 4 |
|----------|-----------------|----------|--|
| Item | Ingredient name | Purpose | Specific requirements |
| | | | mandatory component of zinc stearate. |
| | | | The percentage of zinc from zinc stearate should be calculated based on the molecular weight of zinc stearate. |
| 5234 | ZINC SUCCINATE | A, E, H | When used internally, zinc is a mandatory component of zinc succinate. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' or |
| | | | - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5235 | ZINC SULFATE | A, E | For topical use, the concentration of zinc sulfate must be no more than 5%. |
| | | | For internal use, zinc is a mandatory component of zinc sulfate. |
| | | | When for internal use, the |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Permissible in | ngredients and requirements | | |
|----------------|------------------------------|--------------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| | | | maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25 mg but no more than 50 mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR |
| | | | - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5236 | ZINC SULFATE HEPTAHYDRATE | A , E | For topical use, the concentration of zinc sulfate must be no more than 5%. |
| | | | For internal use, zinc is a mandatory component of zinc sulfate heptahydrate. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| | ngredients and requirements | G.1 | G.1 |
|----------|-----------------------------|----------|--|
| Column 1 | Column 2 | Column 3 | Column 4 |
| Item | Ingredient name | Purpose | Specific requirements |
| | | | OR - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5237 | ZINC SULFATE HEXAHYDRATE | A, E, H | For topical use, the concentration of zinc sulfate must be no more than 5%. |
| | | | For internal use, zinc is a mandatory component of zinc sulfate hexahydrate. |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. |
| | | | When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR |
| | | | - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' |
| 5238 | ZINC SULFATE MONOHYDRATE | A, E, H | When the route of administration is topical the concentration of zinc sulfate in the medicine must be no more |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

| Permissible ingredients and requirements | | | | |
|--|-----------------|----------|--|--|
| Column 1 | Column 2 | Column 3 | Column 4 | |
| Item | Ingredient name | Purpose | Specific requirements | |
| | | | than 5%. | |
| | | | When the medicine is for internal use, zinc is a mandatory component of zinc sulfate monohydrate. | |
| | | | When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. | |
| | | | When for internal use and the maximum recommended daily dose is more than 25 mg but no more than 50 mg of zinc, the medicine requires the following warning statement on the medicine label: | |
| | | | - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR | |
| | | | - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).' | |
| 5239 | ZINC VALERATE | Н | Only for use as an active | |
| | | | homoeopathic ingredient. For internal use, zinc is a mandatory component of zinc valerate. | |
| | | | The percentage of zinc from zinc valerate should be calculated based on the molecular weight of zinc valerate. | |
| 5240 | ZINGERONE | Е | Permitted for use only in combination with other | |

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a

| Permissible ingredients and requirements | | | | |
|--|---------------------------------|----------|---|--|
| Column 1 | Column 2 | Column 3 | Column 4 | |
| Item | Ingredient name | Purpose | Specific requirements | |
| | | | permitted ingredients as a flavour. | |
| | | | If used in a flavour the total flavour concentration in a medicine must be no more than 5%. | |
| 5241 | ZINGIBER OFFICINALE | A, E, H | When for oral use AND the extract ratio is equal to or more than 25:1 AND the equivalent dry weight per dosage unit is equal to or more than 2g, the medicine requires the following warning statement on the medicine label: - (GINGER) 'Individuals taking anticoagulants should seek medical advice before taking this medicine.' AND 'Individuals at risk of bleeding problems should seek advice from their healthcare practitioner prior to taking this medicine'. | |
| 5242 | ZIZIPHUS JUJUBA | A, H | | |
| 5243 | ZIZIPHUS JUJUBA VAR. SPINOSA | A, H | | |
| 5244 | ZIZYPHUS SATIVA | A, H | | |
| 5245 | ZOSTERA MARINA | A, H | | |
| 5246 | ZUCCHINI | Е | | |

Schedule 2—Repeals

Note: See section 7.

Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2019

1 The whole of the instrument

Repeal the instrument.